Brandon P. Moss

Brandon P. Moss

Auto-generated profile, based on publicly available information

Brandon P. Moss

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
PDF file
BMBrandon P Moss
Brandon P Moss
KMKedar R Mahajan
Kedar R Mahajan
RBRobert A Bermel
Robert A Bermel
KHKelsey Hellisz
Kelsey Hellisz
LHLe H Hua
Le H Hua
KFKathryn C Fitzgerald
Kathryn C Fitzgerald
Background: People with multiple sclerosis (MS) may be at higher risk for complications from the 2019 coronavirus (COVID-19) pandemic due to use of immunomodulatory disease modifying therapies (DMTs) and greater need for medical services. Objectives: To evaluate risk factors for COVID-19 susceptibility and describe the pandemic’s impact on healthcare delivery. Methods: Surveys sent to MS patients at Cleveland Clinic, Johns Hopkins, and Vall d’Hebron-Centre d’Esclerosi Múltiple de Catalunya in April and May 2020 collected information about comorbidities, DMTs, exposures, COVID-19 testing/outcomes, health behaviors, and disruptions to MS care. Results: There were 3028/10,816 responders. Suspected or confirmed COVID-19 cases were more likely to have a known COVID-19 contact (odds ratio (OR): 4.38; 95% confidence interval (CI): 1.04, 18.54). In multivariable-adjusted models, people who were younger, had to work on site, had a lower education level, and resided in socioeconomically disadvantaged areas were less likely to follow social distancing guidelines. 4.4% reported changes to therapy plans, primarily delays in infusions, and 15.5% a disruption to rehabilitative services. Conclusion: Younger people with lower socioeconomic status required to work on site may be at higher exposure risk and are potential targets for educational intervention and work restrictions to limit exposure. Providers should be mindful of potential infusion delays and MS care disruption.

7 August 2017 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
BMBrandon P. Moss
Brandon P. Moss
MRMary R. Rensel
Mary R. Rensel
CHCarrie M. Hersh
Carrie M. Hersh

27 July 2017 in Seminars in Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MNManuel Ribeiro Neto
Manuel Ribeiro Neto
BMBrandon Moss
Brandon Moss
MWMary Willis
Mary Willis
DCDaniel Culver
Daniel Culver
Neurosarcoidosis is an uncommon but clinically significant manifestation that will be routinely encountered in sarcoidosis specialty clinics. Overall, neurologic involvement is recognized in 5 to 10% of individuals with sarcoidosis. Neurologic symptoms will be the presenting manifestation of sarcoidosis in approximately one-half of those with neurosarcoidosis. The clinical and imaging features of neurosarcoidosis vary widely, largely depending on the anatomic distribution of the disease. The likelihood of spontaneous resolution is lower than for sarcoidosis in general, and residual functional deficits are not uncommon. Therefore, most patients with neurosarcoidosis require immunosuppressive therapy. Small fiber neuropathy, a recently recognized nongranulomatous parasarcoidosis syndrome, is prevalent in chronic sarcoidosis. The variety of neurologic manifestations, broad differential diagnosis, and complexity of management render neurosarcoidosis an area best served by multidisciplinary teams. Sarcoidologists, neurologists, radiologists, neurosurgeons, endocrinologists, urologists, physiatrists, and physical/occupational therapists all potentially have important roles.

28 March 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GMGabrielle Macaron
Gabrielle Macaron
LBL. E. Baldassari
L. E. Baldassari
KNK. Nakamura
K. Nakamura
SRS. M. Rao
S. M. Rao
MMM. P. McGinley
M. P. McGinley
DCD. S. Conway
D. S. Conway

31 October 2016 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
MMMarisa P. McGinley
Marisa P. McGinley
BMBrandon P. Moss
Brandon P. Moss
JCJeffrey A. Cohen
Jeffrey A. Cohen
Introduction: Monoclonal antibodies are a potent therapeutic approach for relapsing-remitting multiple sclerosis. This group of medications comprises diverse mechanisms of action resulting in both shared and unique adverse effects. Areas covered: The major trials and safety profiles of natalizumab, alemtuzumab, daclizumab, rituximab, and ocrelizumab are discussed. While each drug has a unique safety profile, one of the potential safety concerns for all of these drugs is infection, including for some progressive multifocal leukoencephalopathy. Other potential side effects and required monitoring for each drug are addressed. Expert opinion: The treatment of multiple sclerosis is a balance between efficacy and safety. As a group, these medications are highly effective, but not without notable safety concerns; therefore more research is needed to understand the place these medications hold in the overall treatment algorithm.

1 April 2025 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
GMGiovanna Sophia Manzano
Giovanna Sophia Manzano
JEJames Eaton
James Eaton
MLMichael Levy
Michael Levy
JAJustin Abbatemarco
Justin Abbatemarco
AAAllen J. Aksamit
Allen J. Aksamit
IKIlya Kister
Ilya Kister
Background and ObjectivesNeurosarcoidosis poses a diagnostic and management challenge due to its rarity, phenotypic variability, and lack of randomized controlled studies to guide treatment selecti...